NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Release the
potential of
NUCALA

The first anti-interleukin 5 (IL-5) for severe asthma with an eosinophilic phenotype


As of May 2018, more than 24,000 patients have received NUCALA*"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

*December, 2015 to May, 2018 data sourced from IQVIA and GSK. Claims data based on total number of unique patients who had at least one claim for NUCALA in the United States. Not all patients remained on therapy. Individual results may vary.

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Multiple cell types, including eosinophils, are involved in inflammation"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"2



 

 

Recent findings suggest blood eosinophil levels can be used as a biomarker to initiate therapy in severe asthma."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8

† According to the American Thoracic Society (ATS) and the European Respiratory Society (ERS), severe asthma is a type of asthma that requires treatment with high-dose inhaled corticosteroids (ICS), plus a second controller and/or systemic corticosteroid to prevent it from becoming uncontrolled, or asthma that remains uncontrolled despite this therapy."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"7


In patients with blood eosinophil levels ≥ 150 cells/μL:

NUCALA consistently reduced exacerbations"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"4,"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5

MENSA (Trial 2) STUDY

Primary Endpoint: Exacerbation Frequency
at Week 32"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"4

 
STUDY DESIGN

MUSCA STUDY

Other Endpoint: Exacerbation Frequency
at Week 24"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5

Results are descriptive.
STUDY DESIGN AND PRIMARY ENDPOINT RESULT

CI=confidence interval

SOC=regular treatment with high-dose inhaled corticosteroids (ICS) (defined as ≥880 μg of fluticasone propionate [FP], or the equivalent, per day in patients ≥18 years of age, and ≥440 μg of FP, or the equivalent, per day in patients 12 to 17 years of age) and at least 1 other controller with or without oral corticosteroids (OCS)."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

Exacerbations of asthma were defined as the worsening of asthma that required use of oral/systemic corticosteroids and/or hospitalization and/or emergency department (ED) visits; for patients on maintenance oral/systemic corticosteroids, exacerbations were defined as requiring at least double the existing maintenance dose for at least 3 days.



NUCALA significantly reduced OCS dose while maintaining asthma control"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"6

Patients treated with NUCALA achieved greater reductions in daily OCS dose, while maintaining asthma control, vs placebo (P=0.008). SIRIUS (Trial 3) Study Design:6

Gateway to NUCALA offers resources and services to help meet the changing
access needs of your patients

AFFORDABILITY & ACCESS

Co-pay assistance opportunities for your patients who meet eligibility requirements.§

ACQUISITION

NUCALA is available through a variety of options.

REIMBURSEMENT

Billing and coding, claims and appeal support.

§ Enrollees in government programs are not eligible for co-pay assistance.

The decision by a payer to pay for a specific product is based on many factors. It is always the prescriber’s responsibility to determine the appropriate treatment and submit appropriate codes, charges, and modifiers for treatments provided. Providers should contact third-party payers for specific information on their policies.

PERMANENT J-CODE FOR NUCALA: J2182


Convert blood eosinophil lab results to cells/μL

Chat